NCT03297606 2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
Clinical Trials
15 trialsNCT07383441 2026-02-03
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
SWOG Cancer Research Network
Phase 3 Not yet recruiting
NCT07209059 2025-10-06
FINISH-HL
National Research Center for Hematology, Russia
Phase 2 Recruiting
NCT04511013 2025-09-11
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
Phase 2 Recruiting
NCT03235245 2025-08-01
EBIN
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT04879368 2025-07-17
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
Phase 3 Active not recruiting
NCT02785952 2025-05-21
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT02046733 2024-11-08
STIMULI
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03461952 2024-02-22
NIMBLe
Canadian Cancer Trials Group
Phase 2 Terminated
NCT03443856 2024-01-05
VESTIGE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT03134118 2023-02-21
NIVOTHYM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Unknown
NCT03437200 2023-02-21
CRUCIAL
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT05660993 2022-12-21
Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma
National Research Center for Hematology, Russia
Phase 2 Unknown
NCT02434081 2022-08-24
NICOLAS
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03647839 2021-08-27
MODULATE
Australasian Gastro-Intestinal Trials Group
Phase 2 Completed